Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-HeV/NiV Glycoprotein G Antibody (HENV-32)

Catalog #:   RVV08004 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1, kappa
Applications: ELISA, FCM, Neutralization
Expression system: Mammalian Cells
Overview

Catalog No.

RVV08004

Expression system

Mammalian Cells

Species reactivity

Hendra virus (isolate Horse/Autralia/Hendra/1994) & Nipah virus

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

G, Glycoprotein G, Attachment glycoprotein, Receptor binding protein, RBP

Concentration

2.4 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O89343, Q9IH62

Applications

ELISA, FCM, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

HENV-32

Data Image
  • Bioactivity
    Detects Nipah virus(NiV) Glycoprotein G in indirect ELISAs.
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Development and Validation of a Differentiating Infected from Vaccinated Animals (DIVA) Enzyme-Linked Immunosorbent Assay (ELISA) Strategy for Distinguishing Between Hendra-Infected and Vaccinated Horses., PMID:40143282

Serological and molecular analysis of henipavirus infections in synanthropic fruit bat and rodent populations in the Centre and North regions of Cameroon (2018-2020)., PMID:39994638

Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins., PMID:39704501

Establishing an immune correlate of protection for Nipah virus in nonhuman primates., PMID:39702562

Measures to prevent and treat Nipah virus disease: research priorities for 2024-29., PMID:38964362

Structure and design of Langya virus glycoprotein antigens., PMID:38593070

Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates., PMID:38569014

Prefusion stabilization of the Hendra and Langya virus F proteins., PMID:38214525

Structure and design of Langya virus glycoprotein antigens., PMID:37645760

Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV., PMID:37577376

A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses., PMID:37243163

Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein., PMID:36932063

Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody., PMID:36816187

Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins., PMID:35744614

Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant., PMID:35617431

Architecture and antigenicity of the Nipah virus attachment glycoprotein., PMID:35239409

Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres., PMID:34358146

Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins., PMID:33927387

Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking., PMID:33106487

Vaccines to Emerging Viruses: Nipah and Hendra., PMID:32991264

Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice., PMID:32340278

Establishment of a Highly Sensitive Assay for Detection of Hepatitis E Virus-Specific Immunoglobulins., PMID:31694975

A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101

Superinfective Hepatitis E Virus Infection Aggravates Hepatocytes Injury in Chronic Hepatitis B., PMID:31612388

An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections., PMID:31570878

Henipavirus-like particles induce a CD8 T cell response in C57BL/6 mice., PMID:31561922

Rabies-based vaccine induces potent immune responses against Nipah virus., PMID:31016033

Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody., PMID:30995971

Protection from Hendra virus infection with Canarypox recombinant vaccine., PMID:29263849

The Association of Cytokines and Micronutrients with Hepatitis E Virus Infection During Pregnancy and the Postpartum Period in Rural Bangladesh., PMID:26621563

Structural characterization by transmission electron microscopy and immunoreactivity of recombinant Hendra virus nucleocapsid protein expressed and purified from Escherichia coli., PMID:26196500

Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus., PMID:25948743

Rhabdovirus-based vaccine platforms against henipaviruses., PMID:25320306

Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health., PMID:24572697

Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus., PMID:24508193

Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody., PMID:24130486

Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months., PMID:23867060

Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins., PMID:22915804

Periductal induction of high endothelial venule-like vessels in type 1 autoimmune pancreatitis., PMID:22750968

Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases., PMID:22572886

Henipavirus mediated membrane fusion, virus entry and targeted therapeutics., PMID:22470837

Ephrin-B2 and ephrin-B3 as functional henipavirus receptors., PMID:22227101

A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge., PMID:21689706

Adaptive immune responses during acute uncomplicated and fulminant hepatitis E., PMID:21143520

A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system., PMID:21073718

Targeting of ICAM-1-directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes., PMID:20429814

A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics., PMID:19646266

Development of a neutralization assay for Nipah virus using pseudotype particles., PMID:19559943

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses., PMID:19216624

Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding., PMID:18799571

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-HeV/NiV Glycoprotein G Antibody (HENV-32) [RVV08004]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only